Formycon (FYB.DE) Osake Kurssi
Formycon Kurssi
Liikevaihto on kasvanut 61,9 % vuodessa viimeisten 16 vuoden aikana 44,48 M EUR:een. Osakekohtainen tulos on kasvanut 54,8 % vuodessa viimeisten 9 vuoden aikana. Formyconn nettomarginaali on nyt −145,5 %, laskenut −36,3 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 40,80 EUR, eli yli nykyhintaa 94,7 %. 13 analyytikosta 11 suosittaa ostoa — kokonaiskonsensus on Osta.
Formycon osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Formycon liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Formycon -osakkeesta
The business model of Formycon AG is focused on the development and commercialization of high-quality biosimilar medicines. As a biopharmaceutical company, Formycon specializes in the production of affordable and safe alternatives to expensive biological drugs. By leveraging its proprietary technology and extensive expertise, Formycon aims to address unmet medical needs and improve patient access to therapies. The company collaborates with strategic partners to carry out the research, development, and clinical trials required for regulatory approval. Through its commitment to innovation and cost-effectiveness, Formycon AG strives to contribute to the betterment of healthcare systems worldwide.
Formycon AG is primarily active in the pharmaceutical industry.
The main competitors of Formycon AG in the market include major pharmaceutical companies such as Novartis, Pfizer, Roche, and Sanofi.
Formycon AG is a renowned biopharmaceutical company based in Germany. Established in 2010, the company specializes in the development and production of biosimilars, which are biological drugs highly similar to existing approved products. As a significant player in the industry, Formycon AG aims to make healthcare more affordable and accessible by providing cost-effective biosimilar solutions. The company's expertise lies in the fields of rheumatology, ophthalmology, and oncology, among others. With a strong commitment to research and innovation, Formycon AG has successfully built a robust pipeline of biosimilar candidates and established partnerships with major pharmaceutical companies.
Formycon AG, a renowned pharmaceutical company, has achieved several significant milestones. Notably, the company has successfully developed and commercialized cost-effective biosimilar medicines for various diseases. Formycon AG has gained regulatory approvals for several products, including biosimilar candidates for eye diseases, such as ranibizumab and aflibercept. Moreover, the company has entered into strategic partnerships with prominent pharmaceutical companies, expanding its global reach and market presence. Formycon AG's commitment to innovation and extensive research has driven its success in delivering high-quality and affordable treatments. With its steadfast dedication, Formycon AG continues to redefine healthcare standards and improve patient access to life-saving medications.
Formycon AG is primarily present in Germany, where it is headquartered. As a leading biopharmaceutical company, Formycon operates in various regions across the globe. However, its primary focus remains on the German market, leveraging its expertise in biosimilar drugs. With a strong presence in Germany, Formycon AG aims to contribute to the development and accessibility of high-quality and affordable medicines for patients.
Formycon AG represents values of innovation, excellence, and sustainability in the pharmaceutical industry. Committed to advancing biosimilar drug development, Formycon AG focuses on enhancing patient access to affordable treatments. The company strives to create high-quality and safe biosimilars, providing patients with effective alternatives to expensive originator drugs. Formycon AG's corporate philosophy is rooted in their dedication to delivering high-value propositions that benefit both patients and healthcare systems. By leveraging their expertise in molecular biology and biotechnology, Formycon AG aims to address the unmet medical needs and improve the quality of life for patients worldwide.
Analyytikot asettavat tällä hetkellä Formycon-osakkeelle keskimääräisen tavoitehinnan 50,43 EUR (mediaani: 40,80 EUR), mikä merkitsee +140,7 % viimeisimpään hintaan verrattuna. Konsensus perustuu 13 analyytikkoarvioon.
13 analyytikkoa arvioi tällä hetkellä Formycon-osaketta: 11 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Formycon-yhtiöltä 80,77 M EUR liikevaihtoa ja 0,03 EUR osakekohtaista tulosta.
Formycon-osake (FYB.DE) on listattuna 8 pörssissä, muun muassa: London (0W4N.L), SIX (Zürich) (FYB.SW), XETRA (FYB.DE), Frankfurt (FYB.F), München (FYB.MU), Düsseldorf (FYB.DU), Hamburg (FYB.HM).
The Formycon AG is a biotechnology company specializing in biosimilars. Their business model is to offer more affordable versions of biotechnologically manufactured medicines already on the market. Biosimilars are biologically produced medicines that have similar active ingredients to already approved original preparations and have the same therapeutic effect. The company specializes in developing biosimilars for various therapy areas such as oncology, rheumatology, ophthalmology, and neurology. They focus particularly on established brand products with high value potential. The company conducts research and development in collaboration with partners and clients from the pharmaceutical industry and utilizes its biotechnology expertise in areas such as cell line development, fermentation processes, and the purification of active ingredients. In addition to development, the company aims to successfully market its biosimilars by partnering with established pharmaceutical companies for global distribution channels and rapid entry into key markets. The Formycon AG is currently working on several biosimilars in different stages of clinical development. They also offer consulting services related to biosimilars, leveraging their extensive biotechnology knowledge to support customers in bringing biosimilars to market. In summary, Formycon AG offers a comprehensive range of services including biosimilar development, marketing and distribution support, and biotechnology consulting. Through their focus on biosimilars and partnerships with established pharmaceutical companies, they can quickly and successfully enter the market and establish themselves as a leading provider.
odotettu liikevaihto Formycon on 80,77 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Formycon on 524 754,00 EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Formycon:n hinta-voitto-suhde (P/E) on tällä hetkellä 705,22. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Formycon-osakkeen arvostusta.
Formycon:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,58. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Formycon-osakkeen arvostuskennuslukuna.
Formycon:n Eulpool-laatuscore on 2/10.
Formycon:n ISIN on DE000A1EWVY8. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Formycon:n WKN on A1EWVY. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Formycon:n ticker on FYB.DE. Tämä pörssinoteeraus käytetään Formycon-osakkeiden kauppaan pörssissä.
Formycon osake
Formycon vertaisryhmä
Formycon Ticker
Formycon FIGI
Kaikki tunnusluvut ja syvällinen analyysi Formycon:sta
Meidän osakeanalyysimme Formycon-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Formycon:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: